HIGHLIGHTS
- who: Tao Ouyang and colleagues from the Fudan University, China have published the research work: Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: Monotherapies and Combined Therapies, in the Journal: (JOURNAL)
- what: Subsequently, a randomized, double-blind, phase 3 trial was conducted to compare the efficacy and safety of pembrolizumab with placebo in the treatment of advance HCC patients who previously received sorafenib (KEYNOTE-240) . The results of this study showed the ORR was 76.7% with tolerable toxicity.
- how: The results showed that the median TTP and OS were 7.4 months (95 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.